Back to List View Graph View

Empagliflozin

Empagliflozin is a selective inhibitor of sodium-glucose cotransporter-2 (SGLT2), the transporter that reabsorbs most filtered glucose in the proximal tubule.

Where the papers sit

11 papers from the last 6 months study empagliflozin directly · updated from PubMed 15 Nov 2026

  • Cardiometabolic Drug Assessment

    Empagliflozin quantification is being refined through LC-MS/MS and synchronous fluorescence assays for products and plasma. Clinical work links empagliflozin and semaglutide to endothelial markers in type 2 diabetes. Mechanistic studies instead examine advanced glycation end-products, mitochondrial oxidative damage and PANoptosis in myocardial injury. The cluster therefore has no single therapeutic direction, combining assays with vascular and cardiac biology.

    4 papers · 36.4%

  • Heart Failure and Brain Research

    Heart-failure care is moving toward earlier post-discharge SGLT2 inhibitor initiation and direct comparison of dapagliflozin with empagliflozin. Outcomes center on one-year mortality, acute-care use, hospitalisation and major adverse cardiovascular events in reduced ejection fraction. The cluster also contains nose-to-brain lipid carriers for Alzheimer disease and hyponatremia-related brain-derived neurotrophic factor findings. These CNS studies remain exploratory and do not establish a unified cardiovascular direction.

    4 papers · 36.4%

  • Metformin Combination Therapy

    Metformin-based treatment is being evaluated through fixed-dose empagliflozin combinations and head-to-head comparisons with dapagliflozin and DPP-4 inhibitors. Real-world studies emphasize glycaemic outcomes, treatment effectiveness and safety, including ketoacidosis. Preclinical Parkinsonism work extends the combination question toward neuroprotection involving PI3K and PPARγ signalling. The shared direction is broader comparative and combination use, while clinical benefits across settings remain to be established.

    3 papers · 27.3%

empagliflozin chemical structure

Papers

The 11 papers from the last 6 months that study empagliflozin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Cardiometabolic Drug Assessment (4)
  1. Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial. Journal of diabetes and its complications · 1 Sept 2026 PMID 42679726
  2. Development and validation of a stability-indicating LC-MS/MS method for simultaneous estimation of empagliflozin and metoprolol in pharmaceutical dosage forms with forced degradation studies and computational assessment of degradation products. The Analyst · 29 Jul 2026 PMID 42523027
  3. Advanced glycation end-products exacerbate myocardial ischemia/reperfusion injury by promoting mitochondrial oxidative damage and PANoptosis in diabetes mellitus. Redox biology · 23 May 2026 PMID 42176503
  4. Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples. Scientific reports · 20 May 2026 PMID 42162103
Heart Failure and Brain Research (4)
  1. Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation. ESC heart failure · 22 Sept 2026 PMID 42770322
  2. Hyponatremia correction is associated with increased brain-derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double-blind, placebo-controlled, crossover trial. Journal of neuroendocrinology · 29 Jul 2026 PMID 42522233
  3. Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study. British journal of clinical pharmacology · 26 Jun 2026 PMID 42357835
  4. Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer's disease. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 20 Jun 2026 PMID 42323146
Metformin Combination Therapy (3)
  1. Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China. Journal of diabetes · 28 Sept 2026 PMID 42802896
  2. Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. Scientific reports · 9 Sept 2026 PMID 42711364
  3. Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study. Scientific reports · 24 Jun 2026 PMID 42342812

By study type

Clinical trials (2)
  1. Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial. Journal of diabetes and its complications · 1 Sept 2026 PMID 42679726
  2. Hyponatremia correction is associated with increased brain-derived neurotrophic factor levels: A pilot secondary analysis of a randomized, double-blind, placebo-controlled, crossover trial. Journal of neuroendocrinology · 29 Jul 2026 PMID 42522233
Observational studies and case reports (1)
  1. Effectiveness and Safety of Fixed-Dose Combination Metformin and Empagliflozin in Type 2 Diabetes: A Prospective, Multicenter, Real-World Study From China. Journal of diabetes · 28 Sept 2026 PMID 42802896
Human data, design not indexed (1)
  1. Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples. Scientific reports · 20 May 2026 PMID 42162103
Preclinical: animal, cell and lab studies (4)
  1. Neuroprotective effects of empagliflozin and metformin combined therapy on rotenone induced Parkinsonism in Wistar rats via PI3K and PPARγ modulation. Scientific reports · 9 Sept 2026 PMID 42711364
  2. Development and validation of a stability-indicating LC-MS/MS method for simultaneous estimation of empagliflozin and metoprolol in pharmaceutical dosage forms with forced degradation studies and computational assessment of degradation products. The Analyst · 29 Jul 2026 PMID 42523027
  3. Nose-to-brain delivery of empagliflozin-loaded nanostructured lipid carriers incorporated in-situ gel: Biopharmaceutical evaluation for Alzheimer's disease. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 20 Jun 2026 PMID 42323146
  4. Advanced glycation end-products exacerbate myocardial ischemia/reperfusion injury by promoting mitochondrial oxidative damage and PANoptosis in diabetes mellitus. Redox biology · 23 May 2026 PMID 42176503
Unclassified: not yet indexed with MeSH (3)
  1. Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation. ESC heart failure · 22 Sept 2026 PMID 42770322
  2. Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study. British journal of clinical pharmacology · 26 Jun 2026 PMID 42357835
  3. Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study. Scientific reports · 24 Jun 2026 PMID 42342812